- Our Story
- Our Products
- Our Science
- Our People & Citizenship
-
Investors
- Reports and Filings
- Presentations & Earnings Calls
-
Shares
- Share Price
- Stock Updates
- Equity & Dividend History
- Unpaid & Unclaimed Dividend
- Analyst Coverage
- Shareholding Pattern
- Share Transfer Information
- Buyback
- Details of Shares for transfer to IEPF May 2018
- Notice pursuant to IEPF Rules, May 2018
- Details of Shares for transfer to IEPF May 2019
- Notice Pursuant to IEPF Rules, May 2019
- Details of Shares for transfer to IEPF May 2020
- Notice pursuant to IEPF Rules, May 2020
- Details of Shares for transfer to IEPF May 2021
- Notice pursuant to IEPF Rules, May 2021
- Governance
- Investor Services
-
ESG profile
- Media
- Partners
- Contact Us
Press Releases
Nov
Oct
- Dr. Reddy’s Q2 & H1 FY13 Financial Results: Q2 FY13 Revenues at Rs.28.8 billion (YoY growth of 27%)
- Dr. Reddy’s Laboratories Limited intends to make a recommended public offer for OctoPlus N.V.
- Dr. Reddy's to release Q2 and Half Year FY13 results on October 30, 2012 Earnings call slated for October 30, 6.30 PM IST / 9.00 AM EDT*
- Dr. Reddy’s Custom Pharmaceutical Services (CPS) business expands its manufacturing operations in Mirfield, UK
Sep
Jul
- USFDA lifts import alert from Dr. Reddy’s Chemical Manufacturing Facility at Cuernavaca, Mexico
- Dr. Reddy’s Q1 FY13 Financial Results: Q1 FY13 Revenues at₹25.4 billion, YoY growth of 28%
- Dr. Reddy’s Q1 FY13 Financial Results: Q1 FY13 Revenues at₹25.4 billion, YoY growth of 28%
- Dr. Reddy’s announces the Launch of Atorvastatin Calcium Tablets
- Dr. Reddy's to release Q1 FY13 results on July 19, 2012 Earnings call slated for July 19, 6.30 PM IST / 9.00 AM EST
- Dr. Reddy’s announces the launch of Ibandronate Sodium tablets
May
Apr
Feb
